Adam Klein

Adv. Adam M. Klein specializes in cross-border corporate and finance transactions, including mergers and acquisitions, public offerings, SPACs, Rule 144A offerings, tender offers, 'going private' transactions, reverse takeovers, spin-offs, PIPEs, and private equity and venture capital investments.

Adam advises Israeli SEC-registered companies and dual-listed companies on their corporate governance requirements under Israeli law and under the rules of the SEC, NYSE, and NASDAQ. He also advises foreign companies and investment funds on their acquisitions, financings, investments and business activities in Israel. Adam possesses particular expertise in U.S. public offerings and public offerings of foreign companies on the Tel Aviv Stock Exchange.

In recent years, Adam has advised on some of the largest and most complex merger and acquisition transactions and cross-border public offerings in Israel, in which he has represented multinational corporations and private equity funds in Israeli transactions, as well as Israeli corporations and global investment banks in overseas transactions.

Adam is recognized as one of Israel's leading attorneys in the capital markets, corporate and M&A fields by Chambers & Partners and The Legal 500.

Adam advised the Ethics Committee of the Israel Bar Association on rules of conduct for attorneys under the Sarbanes-Oxley Act; crafted the first U.S.-style Shareholder Rights Plan ('Poison Pill') in Israel, which enables public companies to defend themselves from hostile takeovers; and lecturers to professional audiences on a variety of legal topics.

From 1992 to 1999, Adam was an associate in the Corporate and Financial Services Department of Willkie Farr & Gallagher, New York.

Adam is a member of the firm's Executive Committee.

Associate, Willkie Farr & Gallagher, 1992-99.

Israel Bar, 2000; New York State Bar, 1992.

JD, Columbia Law School, 1991; Notes Editor, Columbia Journal of Transnational Law; BA, English Literature, Yeshiva University, 1987.